<html xmlns:v="urn:schemas-microsoft-com:vml" xmlns:o="urn:schemas-microsoft-com:office:office" xmlns="http://www.w3.org/TR/REC-html40">

<head>
<meta http-equiv="Content-Language" content="en-us">
<meta name="GENERATOR" content="Microsoft FrontPage 6.0">
<meta name="ProgId" content="FrontPage.Editor.Document">
<meta http-equiv="Content-Type" content="text/html; charset=windows-1252">



<title>Hi-R-Ed Online</title>
<style>
<!--
p
	{margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman";
	}
p.MsoNormal
	{mso-style-parent:"";
	margin-bottom:.0001pt;
	font-size:12.0pt;
	font-family:"Times New Roman";
	margin-left:0in; margin-right:0in; margin-top:0in}
table.MsoTableGrid
	{border:1.0pt solid windowtext;
	font-size:10.0pt;
	font-family:"Times New Roman";
	}
span.MsoCommentReference
	{}
-->
</style>
</head>

<body bgcolor="#DBCEAC">

<table border="1" cellspacing="0" cellpadding="2" width="950" style="border-collapse:collapse" bordercolor="#013554">
  <tr style="height: .75pt">
    <td width="17%" valign="top" style="width: 9%; padding: 3.0pt; background: #006B85; " bordercolor="#013554">
    <p>
    <a target="_blank" href="../Instructions2.htm">
    <img border="0" src="images/Instructions-LC.jpg" width="90" height="68"></a><font face="Copperplate Gothic Bold" size="1" color="#FFFFFF"><b> </b>
    <font color="#FFFFFF">
    Instructions</font></font></p>
    <p>
    <a href="../BH_home.htm">
    <img border="0" src="images/Take_Another_Course-LC2.jpg" width="89" height="63"></a><font face="Copperplate Gothic Bold" size="1" color="#FFFFFF"><b>&nbsp;&nbsp;&nbsp;
    </b>
    <font color="#FFFFFF">Take Another Course</font></font></p>
    <p><u><font size="6" color="#0000FF" face="Arial">
    <b>
    <a target="_blank" href="CCM%20Evaluation.htm">
    <img border="0" src="images/Resources-LC.jpg" width="90" height="68"></a><a href="../IVAbx/cellulitis%20quiz.asp"> </a> </b></font></u>
    <font color="#FFFFFF" face="Copperplate Gothic Bold" size="1">Post-Test</font></p>
    <p>
    &nbsp;<p>
    &nbsp;</td>
    <td width="89%" style="padding: 3.0pt" bgcolor="#006B85" valign="top">
    <table border="1" cellspacing="1" width="100%" cellpadding="4" bordercolor="#013554" id="table3" style="border-collapse: collapse">
      <tr>
        <td width="5%" bgcolor="#FFFFFF" valign="top">
<p style="line-height: 115%; text-align: left; direction: ltr; unicode-bidi: embed; word-break: normal; punctuation-wrap: hanging; margin-left: 0in; margin-right: 0in; margin-top: 0pt; margin-bottom: 10.0pt">
<span style="font-family: Arial; color: #043D4F; font-weight: bold; vertical-align: baseline">
<font size="4">Clinical Pearl</font></span></p>
<p style="text-align: left; direction: ltr; unicode-bidi: embed; vertical-align: baseline; punctuation-wrap: simple; margin-top: 0; margin-bottom: 0pt">
<span style="font-family: Arial; color: black; font-style: normal">
<font size="3">We are now going to examine some of the pharmacological treatment 
options. However, it should be noted that</font></span><span style="font-family: Arial; color: black; font-style: normal; vertical-align: baseline"><font size="3"> 
when possible both pharmacological and non-pharmacological treatment options 
should be used concurrently.</font></span></p>
<p style="text-align: left; direction: ltr; unicode-bidi: embed; vertical-align: baseline; punctuation-wrap: simple; margin-top: 0; margin-bottom: 0pt">&nbsp;</p>
<p style="text-align: left; direction: ltr; unicode-bidi: embed; vertical-align: baseline; punctuation-wrap: simple; margin-top: 0; margin-bottom: 0pt">
<span style="font-family: Arial; color: #043D4F; font-weight: bold; vertical-align: baseline">
<font size="4">Pharmacological Options</font></span></p>
<div class="O0" style="language:en-US;line-height:normal;margin-top:0pt;
margin-bottom:0pt;margin-left:.26in;margin-right:0in;text-indent:-.26in;
text-align:left;direction:ltr;unicode-bidi:embed;vertical-align:baseline;
mso-line-break-override:none;word-break:normal;punctuation-wrap:hanging">
	<span style="color: #006983; font-family: Arial">&nbsp; •</span><span style="font-family: Arial; color: black">Antimuscarinic 
	agents</span></div>
<div class="O0" style="language:en-US;line-height:normal;margin-top:0pt;
margin-bottom:0pt;margin-left:.26in;margin-right:0in;text-indent:-.26in;
text-align:left;direction:ltr;unicode-bidi:embed;vertical-align:baseline;
mso-line-break-override:none;word-break:normal;punctuation-wrap:hanging">
	<span style="color: #006983; font-family: Arial">&nbsp; •</span><span style="font-family: Arial; color: black">Alpha-adrenergic 
	antagonist</span></div>
<div class="O0" style="language:en-US;line-height:normal;margin-top:0pt;
margin-bottom:0pt;margin-left:.26in;margin-right:0in;text-indent:-.26in;
text-align:left;direction:ltr;unicode-bidi:embed;vertical-align:baseline;
mso-line-break-override:none;word-break:normal;punctuation-wrap:hanging">
	<span style="color: #006983; font-family: Arial">&nbsp; •</span><span style="font-family: Arial; color: black">Beta-3 
	adrenergic agonist</span></div>
<div class="O0" style="language:en-US;line-height:normal;margin-top:0pt;
margin-bottom:0pt;margin-left:.26in;margin-right:0in;text-indent:-.26in;
text-align:left;direction:ltr;unicode-bidi:embed;vertical-align:baseline;
mso-line-break-override:none;word-break:normal;punctuation-wrap:hanging">
	<span style="color: #006983; font-family: Arial">&nbsp; •</span><span style="font-family: Arial; color: black">Botulinum 
	toxin A</span><p style="text-align: left; direction: ltr; unicode-bidi: embed; vertical-align: baseline; punctuation-wrap: simple; text-indent: oin; margin-top: 4.32pt; margin-bottom: 0pt">
	<span style="font-size: 12.0pt; font-family: Arial; color: black; font-weight: normal">
	Antimuscarinic or anticholinegic agents are recommended by the Agency for 
	Health Research and Quality (</span><span style="font-size: 12.0pt; font-family: Arial; color: black; font-weight: normal; vertical-align: baseline">the
	</span>
	<span style="font-size: 12.0pt; font-family: Arial; color: black; font-weight: normal">
	AHRQ), formerly known as the Agency for Health</span><span style="font-size: 12.0pt; font-family: Arial; color: black; font-weight: normal; vertical-align: baseline"> 
	Care Policy and Research (the </span>
	<span style="font-size: 12.0pt; font-family: Arial; color: black; font-weight: normal">
	AHCPR), as the first line of therapy for UUI and OAB. </span></p>
	<p style="text-align: left; direction: ltr; unicode-bidi: embed; vertical-align: baseline; punctuation-wrap: simple; text-indent: oin; margin-top: 4.32pt; margin-bottom: 0pt">
	<span style="font-size: 12.0pt; font-family: Arial; color: black; font-weight: normal">
	How</span><span style="font-size: 12.0pt; font-family: Arial; color: black; font-weight: normal; vertical-align: baseline"> 
	these medicines work is interesting.</span><span style="font-size: 12.0pt; font-family: Arial; color: black; font-weight: normal"> 
	They interfere with impulses from the parasympathetic nerves that cause the 
	detrusor muscle of the bladder to contract. This causes the detrusor muscle 
	to relax and the receptors responsible for bladder contraction to be 
	inhibited. </span></p>
	<p style="text-align: left; direction: ltr; unicode-bidi: embed; vertical-align: baseline; punctuation-wrap: simple; text-indent: oin; margin-top: 4.32pt; margin-bottom: 0pt">
	<span style="font-size: 12.0pt; font-family: Arial; color: black; font-weight: normal">
	Drug</span><span style="font-size: 12.0pt; font-family: Arial; color: black; font-weight: normal; vertical-align: baseline"> 
	class options are listed above.</span></p>
	<p>
	<span style="font-family: Arial; color: #043D4F; font-weight: bold; vertical-align: baseline">
	<font size="4">Antimuscarinics</font></span></div>
<div class="O0" style="language:en-US;line-height:normal;margin-top:0pt;
margin-bottom:0pt;margin-left:.5in;margin-right:0in;text-indent:-.5in;
text-align:left;direction:ltr;unicode-bidi:embed;vertical-align:baseline;
mso-line-break-override:none;word-break:normal;punctuation-wrap:hanging">
	<span style="font-size: 12.0pt; font-family: Arial; color: black">Antimuscarinics</span><span style="font-size: 12.0pt; font-family: Arial; color: black; vertical-align: baseline"> 
	are used to address the following four issues:</span><p style="text-align: left; direction: ltr; unicode-bidi: embed; vertical-align: baseline; punctuation-wrap: simple; margin-left: 0in; margin-top: 4.32pt; margin-bottom: 0pt">
	<span style="font-size: 12.0pt; font-family: Arial; color: black">1. 
	Inhibiting overactive detrusor contractions</span></p>
	<p style="text-align: left; direction: ltr; unicode-bidi: embed; vertical-align: baseline; punctuation-wrap: simple; margin-left: 0in; margin-top: 4.32pt; margin-bottom: 0pt">
	<span style="font-size: 12.0pt; font-family: Arial; color: black">2. 
	Increasing bladder capacity and the time between each void</span></p>
	<p style="text-align: left; direction: ltr; unicode-bidi: embed; vertical-align: baseline; punctuation-wrap: simple; margin-left: 0in; margin-top: 4.32pt; margin-bottom: 0pt">
	<span style="font-size: 12.0pt; font-family: Arial; color: black">3. 
	Decreasing day and nighttime voiding frequency</span></p>
	<p style="text-align: left; direction: ltr; unicode-bidi: embed; vertical-align: baseline; punctuation-wrap: simple; margin-left: 0in; margin-top: 4.32pt; margin-bottom: 0pt">
	<span style="font-size: 12.0pt; font-family: Arial; color: black">4. 
	Decreasing the number of urge urinary incontinence episodes</span></p>
	<p style="text-align: left; direction: ltr; unicode-bidi: embed; vertical-align: baseline; punctuation-wrap: simple; text-indent: 0in; margin-left: -0.5in; margin-top: 4.32pt; margin-bottom: 0pt">
	<span style="font-size: 12.0pt; font-family: Arial; color: black; font-weight: normal">The actions of antimuscarinics are shown below as reported by Paul Taylor</span><span style="font-size: 12.0pt; font-family: Arial; color: black; font-weight: normal; vertical-align: baseline"> 
	in </span>
	<span style="font-size: 12.0pt; font-family: Arial; color: black; font-weight: normal">2005. 
	</span></p>
	<p style="text-align: left; direction: ltr; unicode-bidi: embed; vertical-align: baseline; punctuation-wrap: simple; margin-top: 4.32pt; margin-bottom: 0pt">
	<span style="font-size: 12.0pt; font-family: Arial; color: black; font-weight: normal; font-style: italic">(Taylor, P. Pharmacologic Management of Overactive Bladder. JWOCN. 
	Supplement 1.2005;32:516-523)</span></p>
	<p style="text-align: left; direction: ltr; unicode-bidi: embed; vertical-align: baseline; punctuation-wrap: simple; text-indent: 0in; margin-left: -0.5in; margin-top: 4.32pt; margin-bottom: 0pt">
	<span style="font-size: 12.0pt; font-family: Arial; color: black; font-weight: normal">UUI episodes decreased from 40-70% for those with “wet” OAB. These 
	muscarinic receptors are found throughout the body and contribute to 
	unwanted adverse effects experienced. These adverse effects are more 
	problematic in the elderly and occur more frequently and tend to be more 
	severe. Contraindications for these types of medications include urinary and 
	gastric retention and uncontrolled narrow-angle glaucoma.</span></p>
	<p><span style="font-family: Arial; font-weight: 700">
	<font size="4" color="#043D4F">Adverse Effects of Antimuscarinics</font></span></div>
<div class="O0" style="language:en-US;line-height:normal;margin-top:0pt;
margin-bottom:0pt;margin-left:.26in;margin-right:0in;text-indent:-.26in;
text-align:left;direction:ltr;unicode-bidi:embed;vertical-align:baseline;
mso-line-break-override:none;word-break:normal;punctuation-wrap:hanging">
	<span style="color: #006983; font-family: Arial">
	<b>&nbsp; </b>•</span><span style="font-family: Arial; color: black">Dry 
	mouth</span></div>
<div class="O0" style="language:en-US;line-height:normal;margin-top:0pt;
margin-bottom:0pt;margin-left:.26in;margin-right:0in;text-indent:-.26in;
text-align:left;direction:ltr;unicode-bidi:embed;vertical-align:baseline;
mso-line-break-override:none;word-break:normal;punctuation-wrap:hanging">
	<span style="color: #006983; font-family: Arial">&nbsp; •</span><span style="font-family: Arial; color: black">Constipation</span></div>
<div class="O0" style="language:en-US;line-height:normal;margin-top:0pt;
margin-bottom:0pt;margin-left:.26in;margin-right:0in;text-indent:-.26in;
text-align:left;direction:ltr;unicode-bidi:embed;vertical-align:baseline;
mso-line-break-override:none;word-break:normal;punctuation-wrap:hanging">
	<span style="color: #006983; font-family: Arial">&nbsp; •</span><span style="font-family: Arial; color: black">Blurred 
	vision</span></div>
<div class="O0" style="language:en-US;line-height:normal;margin-top:0pt;
margin-bottom:0pt;margin-left:.26in;margin-right:0in;text-indent:-.26in;
text-align:left;direction:ltr;unicode-bidi:embed;vertical-align:baseline;
mso-line-break-override:none;word-break:normal;punctuation-wrap:hanging">
	<span style="color: #006983; font-family: Arial">&nbsp; •</span><span style="font-family: Arial; color: black">Sedation</span></div>
<div class="O0" style="language:en-US;line-height:normal;margin-top:0pt;
margin-bottom:0pt;margin-left:.26in;margin-right:0in;text-indent:-.26in;
text-align:left;direction:ltr;unicode-bidi:embed;vertical-align:baseline;
mso-line-break-override:none;word-break:normal;punctuation-wrap:hanging">
	<span style="color: #006983; font-family: Arial">&nbsp; •</span><span style="font-family: Arial; color: black">Cognitive 
	impairment</span></div>
<div class="O0" style="language:en-US;line-height:normal;margin-top:0pt;
margin-bottom:0pt;margin-left:.26in;margin-right:0in;text-indent:-.26in;
text-align:left;direction:ltr;unicode-bidi:embed;vertical-align:baseline;
mso-line-break-override:none;word-break:normal;punctuation-wrap:hanging">
	<span style="color: #006983; font-family: Arial">&nbsp; •</span><span style="font-family: Arial; color: black">EKG 
	changes</span></div>
<div class="O0" style="language:en-US;line-height:normal;margin-top:0pt;
margin-bottom:0pt;margin-left:.26in;margin-right:0in;text-indent:-.26in;
text-align:left;direction:ltr;unicode-bidi:embed;vertical-align:baseline;
mso-line-break-override:none;word-break:normal;punctuation-wrap:hanging">
	<span style="color: #006983; font-family: Arial">&nbsp; •</span><span style="font-family: Arial; color: black">Decreased 
	sweating</span><p style="text-align: left; direction: ltr; unicode-bidi: embed; vertical-align: baseline; punctuation-wrap: simple; text-indent: 0in; margin-left: -0.26in; margin-top: 4.32pt; margin-bottom: 0pt">
	<span style="font-size: 12.0pt; font-family: Arial; color: black; font-weight: normal">
	Dry mouth in addition to being bothersome can contribute to tooth decay and 
	poor fitting dentures. Chronic use of these medications can cause tooth loss 
	and tooth decay as well. Constipation can increase the risk of UTI’s due to 
	incomplete bladder emptying, and increase the risk of bladder prolapse in 
	women. Blurred vision and sedation have significant safety implications in 
	terms of accidents and injuries while walking or driving. Cognitive 
	impairment may manifest as acute confusion (delirium), short term memory 
	impairment or nightmares. EKG changes most commonly are related to Q-T 
	interval prolongation </span>
	<span style="font-size: 12.0pt; font-family: Arial; color: black; font-weight: normal; font-style: italic">
	(this is the interval between the start of the Q wave and the end of the T 
	wave in the heart’s electrical cycle)</span><span style="font-size: 12.0pt; font-family: Arial; color: black; font-weight: normal">. 
	Decreased sweating can be quite dangerous in the summer months and 
	contribute to hyperthermia. It is a good idea to teach your clients that 
	these medications take a couple of weeks before an effect is seen. </span>
</div>
<p style="margin-top: 0; margin-bottom: 0">&nbsp;</p>
<p style="text-align: left; direction: ltr; unicode-bidi: embed; vertical-align: baseline; punctuation-wrap: hanging; margin-top: 0pt; margin-bottom: 0pt">
<font color="#043D4F" size="4">
<span style="font-family: Arial; font-weight: 700">Antimuscarinics seen in your 
clinical practice</span></font></p>
		<div class="O0" style="language:en-US;line-height:normal;margin-top:0pt;
margin-bottom:0pt;margin-left:.26in;margin-right:0in;text-indent:-.26in;
text-align:left;direction:ltr;unicode-bidi:embed;vertical-align:baseline;
mso-line-break-override:none;word-break:normal;punctuation-wrap:hanging">
			<b>
			<span style="color: #006983; font-family: Arial">&nbsp; •</span></b><span style="font-family: Arial; color: black">Darifenacin 
			(Enablex)</span></div>
		<div class="O0" style="language:en-US;line-height:normal;margin-top:0pt;
margin-bottom:0pt;margin-left:.26in;margin-right:0in;text-indent:-.26in;
text-align:left;direction:ltr;unicode-bidi:embed;vertical-align:baseline;
mso-line-break-override:none;word-break:normal;punctuation-wrap:hanging">
			<span style="color: #006983; font-family: Arial">&nbsp; •</span><span style="font-family: Arial; color: black">Oxybutynin 
			(Ditropan, Oxytrol)</span></div>
		<div class="O0" style="language:en-US;line-height:normal;margin-top:0pt;
margin-bottom:0pt;margin-left:.26in;margin-right:0in;text-indent:-.26in;
text-align:left;direction:ltr;unicode-bidi:embed;vertical-align:baseline;
mso-line-break-override:none;word-break:normal;punctuation-wrap:hanging">
			<span style="color: #006983; font-family: Arial">&nbsp; •</span><span style="font-family: Arial; color: black">Solifenacin 
			(VESIcare)</span></div>
		<div class="O0" style="language:en-US;line-height:normal;margin-top:0pt;
margin-bottom:0pt;margin-left:.26in;margin-right:0in;text-indent:-.26in;
text-align:left;direction:ltr;unicode-bidi:embed;vertical-align:baseline;
mso-line-break-override:none;word-break:normal;punctuation-wrap:hanging">
			<span style="color: #006983; font-family: Arial">&nbsp; •</span><span style="font-family: Arial; color: black">Tolterodine 
			(Detrol)</span></div>
		<div class="O0" style="language:en-US;line-height:normal;margin-top:0pt;
margin-bottom:0pt;margin-left:.26in;margin-right:0in;text-indent:-.26in;
text-align:left;direction:ltr;unicode-bidi:embed;vertical-align:baseline;
mso-line-break-override:none;word-break:normal;punctuation-wrap:hanging">
			<span style="color: #006983; font-family: Arial">&nbsp; •</span><span style="font-family: Arial; color: black">Trospium 
			(Sanctura)</span></div>
		<p style="text-align: left; direction: ltr; unicode-bidi: embed; vertical-align: baseline; punctuation-wrap: simple; margin-top: 4.32pt; margin-bottom: 0pt">
		<span style="font-size: 12.0pt; font-family: Arial; color: black">The 
		drugs listed</span><span style="font-size: 12.0pt; font-family: Arial; color: black; vertical-align: baseline"> 
		are all available</span><span style="font-size: 12.0pt; font-family: Arial; color: black"> 
		in tablet form. Oxybutynin also comes in a transdermal patch, a 10% gel, 
		a bladder instillation solution and an OTC formulation. And all of 
		these, with the exception of Trospium, are metabolized via the 
		cytochrome P450 system and may contribute to adverse drug-drug 
		interactions. It is thought that Trospium, since it is eliminated 
		unchanged, may have a lower potential for drug-drug interactions. It is 
		more water soluble and is less likely to cross the blood brain barrier. 
		Of note, there are fewer complaints of dry mouth with topical Oxybutynin 
		than the oral formulation.</span></p>
<p><font face="Calibri" size="1" color="#FFFFFF">Rick Fields-Gardner</font></td>
      </tr>
    </table>
    </td>
  </tr>
</table>

<p class="MsoBodyTextIndent"><b><font size="1" color="#015384">Click on the link 
at left to go to your desired page:&nbsp;</font></b></p>

<p><b><font size="1" color="#015384"><font color="#015384">
<a href="(intro).htm"><font color="#015384">Page 1</font></a></font><font size="1">&nbsp;</font>
<a href="(p2).htm"><font color="#015384">Page 2</font></a>&nbsp; </font>
<font size="1" color="#808080"><a href="(p4).htm">
<font color="#015384">Page 3</font></a></font><font size="1" color="#015384">&nbsp; </font><font size="1" color="#6699FF">
	<a href="(p4).htm"><font color="#015384">Page 4</font></a></font><font size="1" color="#015384">&nbsp; </font><font size="1" color="#6699FF"> 
	<a href="(p5).htm">
<font color="#015384">Page 5</font></a><font size="1" color="#015384">&nbsp; </font> 
<font color="#808080"><a href="(p6).htm"><font color="#015384">Page 6</font></a></font><font size="1" color="#015384">&nbsp;
</font></font>
	<a href="(p7).htm">
	<font size="1" color="#015384">Page 7</font></a><font color="#015384" size="1">&nbsp;
	<a href="(p8).htm"><font color="#015384">Page 8</font></a>&nbsp; </font>
<font size="1" color="#808080"><a href="(p9).htm">
<font color="#015384">Page 9</font></a></font><font size="1" color="#015384">&nbsp; 
<a target="_blank" href="CCM%20Evaluation.htm">
<font color="#015384">Post-Test</font></a></font></b></p>

<table border="0" width="100%" id="table1">
	<tr>
		<td width="73"><i><a href="(p6).htm">
<font color="#015384" face="Arial" style="font-size: 11pt">Continue</font></a></i></td>
		<td>
		<img border="0" src="../Diab&Exer/images/arrow.gif" width="50" height="31"></td>
	</tr>
</table>

<h5 align="center"><font face="Arial" size="1">2013 Hi-R-Ed Online University. All courses posted on 
    this site are the property of Hi-R-Ed Online University unless otherwise 
    stated. Courses may not be copied or transferred in electronic, printed, or 
    other forms, or modified for any purpose without explicit written consent of Hi-R-Ed Online University.</font></h5>

<p align="center">&nbsp;</p>

</body>

</html>